At MDA, we believe in the power of research and the importance of building relationships among families, clinicians, and the scientists making discoveries to advance treatments and therapies. We invite individuals living with myasthenia gravis (MG), as well as caregivers and loved ones, to attend the MDA Engage MG Symposium taking place on Nov. 2 in Durham, NC.
We are honored to have Dr. James F. Howard Jr. as the event chair. Dr. Howard recently retired after an extensive career as the chief of Neuromuscular Disorders at the University of North Carolina Hospitals in Chapel Hill, NC. At the Engage event, we invite you to join us in celebrating Dr. Howard’s commitment to MDA and the families he served throughout his 40-year career as an MDA Care Center director.
For a complete list of speakers and topics, and to register for the symposium, click here. This event is free to attend and pre-registration by Oct. 28 is required. A pre-event social gathering will take place on Nov. 1 at 6:30 p.m. at the symposium hotel.
A note from the MG symposium event chair
The last decade has seen a tremendous interest in MG by the research community and the pharmaceutical industry. In late 2017, the MG community saw the first-ever drug approved for the treatment of their disease. This interest continues. While this is gratifying, our work and your work continues. The gains we have made and will continue to make require a partnership among the scientific community, industry, and, most importantly, you, the patient.
MDA, one of our significant partners, has assembled this symposium to provide you with the latest information we have on MG. Topics that will be covered include emerging therapeutic strategies and how drugs are developed, how to navigate the clinical trial arena, the best practices in clinical care, and how to navigate community and federal resources.
On behalf of the faculty and organizers, we welcome you to this exciting program.
— JF Howard
The MDA Engage MG Symposium is generously sponsored in part by Alexion, Momenta, and RA Pharma.
